Market News & Trends
GlycoNex Announces First Patient Dosed in Phase 3 Clinical Trial for Denosumab Biosimilar
GlycoNex, Inc. recently announced the first patient has been dosed in the Phase 3 clinical trial of its denosumab biosimilar, SPD8. This marks the initiation…
RTI Surgical Transforms Into Evergen, a Leading CDMO in Regenerative Medicine
RTI Surgical recently unveiled its new corporate identity as Evergen, signaling its strategic evolution into a premier Contract Development and Manufacturing Organization (CDMO) providing biosolutions…
Immutep Announces Initial Safety Data From First-in-Human Phase 1 Trial Evaluating IMP761
Immutep Limited recently announced favorable initial safety data from the placebo-controlled, double-blind first-in-human Phase 1 study evaluating IMP761. Through the first three of five single…
Palvella Therapeutics Announces Closing of Merger With Pieris Pharmaceuticals & Concurrent Private Placement of $78.9 Million
Palvella Therapeutics, Inc. recently announced the completion of its previously announced merger with Pieris Pharmaceuticals, Inc. (Pieris). The combined company will operate under the name…
Verge Genomics Announces New Development Candidate, a Novel Maintenance Therapy for Long-Term Weight Management
Verge Genomics recently announced the nomination of a second development candidate, VRG201, targeting long-term weight management and metabolic homeostasis. VRG201 is an oral, first-in-class therapy…
Innoviva Specialty Therapeutics Signs Exclusive Distribution & Licensing Agreement
Innoviva Specialty Therapeutics, Inc. recently announced it has entered into an exclusive distribution and license agreement with Basilea Pharmaceutica Ltd, Allschwil for the commercialization of…
Atsena Therapeutics Announces Dosing Completed in Part A of Phase 1/2 Clinical Trial Evaluating Gene Therapy to Treat X-linked Retinoschisis
Atsena Therapeutics recently announced dosing has been completed in Part A of the LIGHTHOUSE study, a Phase 1/2 clinical trial evaluating subretinal injection of ATSN-201…
HUTCHMED to Receive Milestone Payment From Takeda
HUTCHMED recently announced it will receive a $10-million milestone payment by its partner Takeda. Takeda received a national reimbursement recommendation for FRUZAQLA (fruquintinib) for patients…
Assertio Announces Results of Rolvedon Injection Same-Day Dosing Clinical Study
Assertio Holdings, Inc. recently announced results of a clinical trial investigating the utility of Rolvedon (eflapegrastim-xnst) injection when dosed the same day of chemotherapy for…
VelaLabs Announces Strategic Partnership to Support Biological Drugs Development
VelaLabs GmbH has signed a Memorandum of Understanding (MoU) with EarlyHealth Group to establish comprehensive solutions for the development of advanced biological drugs. Under the…
Conduit Pharmaceuticals to Revolutionize Drug Development Through Agreement to Use AI & Cybernetics
Conduit Pharmaceuticals Inc. recently announced it has entered into an agreement with SARBORG Limited to leverage an advanced artificial intelligence (AI) and cybernetics platform to…
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma
Immuneering Corporation recently announced the US FDA has granted Fast Track designation for its lead clinical-stage program, IMM-1-104, as a treatment for patients with unresectable…
PDC*line Pharma Presents Primary Clinical Results From Phase I/II Trial on PDC*lung01 Cancer Vaccine
PDC*line Pharma recently announced the primary clinical results from the last cohort of patients in its Phase I/II clinical trial with PDC*lung01 (PDC-LUNG-101, NCT03970746), in…
Enterome Presents Encouraging Initial Clinical Data on EO4010 in Colorectal Cancer
Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for cancer based on its unique Mimicry platform, recently announced initial clinical data from the ongoing Phase…
Etherna Announces Discovery of Novel mRNA Immunotherapeutic Delivered Via Lipid Nanoparticles That Has Demonstrated Ability to Eradicate Tumors in Preclinical Models
etherna, a biotech company pioneering mRNA and lipid-based-nanoparticle (LNP) technologies, recently announced the publication of pre-clinical data showing the therapeutic potential of a new mixture…
Monte Rosa Therapeutics Announces Closing of Global License Agreement With Novartis
Monte Rosa Therapeutics, Inc. recently announced the closing of its previously announced global exclusive development and commercialization license agreement with Novartis to advance VAV1-directed MGDs,…
Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial
Candel Therapeutics, Inc. recently announced results from a multicenter phase 3 clinical trial evaluating CAN-2409 viral immunotherapy in localized prostate cancer patients. In the US alone,…
EORTC & Immunocore Announce Enrolment of First Patient Onto the Only Active Phase 3 Adjuvant Trial in Uveal Melanoma
The European Organisation for Research and Treatment of Cancer (EORTC) and Immunocore Holdings plc recently announced the randomization of the first patient in the Phase…
ProQR Therapeutics Announces $8.1 Million in New Funding From Rett Syndrome Research Trust to Expand RNA Editing Collaboration
ProQR Therapeutics NV recently announced an expansion of its collaboration with the Rett Syndrome Research Trust (RSRT). Building on the initial $1 million research grant…
Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-Escalation Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib in Patients With Relapsed/Refractory Lymphoid Malignancies
Prelude Therapeutics Incorporated recently announced the presentation of the first interim clinical data from its ongoing open-label, dose-escalation trial of PRT2527, a potent and highly…
